Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
Conditions
Interventions
WVE-120102
Placebo
Locations
26
United States
University of California San Diego
La Jolla, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
The Ohio State University
Columbus, Ohio, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Westmead Hospital
Sydney, New South Wales, Australia
Start Date
July 17, 2017
Primary Completion Date
May 10, 2021
Completion Date
May 10, 2021
Last Updated
April 25, 2022
NCT02855476
NCT01574053
NCT04120493
NCT05107128
NCT03664804
NCT00670709
Lead Sponsor
Wave Life Sciences Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions